<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="27162">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02753127</url>
  </required_header>
  <id_info>
    <org_study_id>CanStem303C</org_study_id>
    <secondary_id>BB608-303CRC</secondary_id>
    <secondary_id>2016-001627-31</secondary_id>
    <nct_id>NCT02753127</nct_id>
  </id_info>
  <brief_title>A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer</brief_title>
  <acronym>CanStem303C</acronym>
  <official_title>A Phase III Study of BBI-608 in Combination With 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CRC).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Biomedical, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Biomedical, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an international multi-center, prospective, open-label, randomized phase 3 trial of
      the cancer stem cell pathway inhibitor napabucasin plus standard bi-weekly FOLFIRI versus
      standard bi-weekly FOLFIRI in patients with previously treated metastatic colorectal cancer
      (CRC).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>36 months</time_frame>
    <description>To assess the effect of napabucasin plus biweekly FOLFIRI versus biweekly FOLFIRI on the Overall Survival of patients with previously treated metastatic colorectal cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival in biomarker positive patients</measure>
    <time_frame>36 months</time_frame>
    <description>Overall Survival in biomarker positive patients [ Time Frame: 36 months ] [ Designated as safety issue: No ] To assess the effect of napabucasin plus biweekly FOLFIRI versus biweekly FOLFIRI on the Overall Survival of patients with previously treated metastatic colorectal cancer in biomarker positive patients. This biomarker-positive sub-population is defined as those patients with phospho-STAT3 and/or nuclear β-catenin positivity on immunohistochemical (IHC) staining of Formalin Fixed Paraffin Embedded (FFPE) archival tissue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>36 months</time_frame>
    <description>Defined as the time from randomization to the first objective documentation of disease progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival in biomarker positive patients</measure>
    <time_frame>36 months</time_frame>
    <description>Defined as the time from randomization to the first objective documentation of disease progression or death due to any cause. This biomarker-positive sub-population is defined as those patients with nuclear phospho-STAT3 and/or nuclear β-catenin positivity on immunohistochemical (IHC) staining of Formalin Fixed Paraffin Embedded (FFPE) archival tissue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>36 months</time_frame>
    <description>Defined as the proportion of patients with a documented complete response or partial response (CR + PR) based on RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>36 months</time_frame>
    <description>Defined as the proportion of patients with a documented complete response, partial response, and stable disease (CR + PR + SD) based on RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate in biomarker positive patients</measure>
    <time_frame>36 months</time_frame>
    <description>Defined as the proportion of patients with a documented complete response or partial response (CR + PR) based on RECIST 1.1. This biomarker-positive sub-population is defined as those patients with phospho-STAT3 and/or nuclear β-catenin positivity on immunohistochemical (IHC) staining of Formalin Fixed Paraffin Embedded (FFPE) archival tissue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate in biomarker positive patients</measure>
    <time_frame>36 months</time_frame>
    <description>Defined as the proportion of patients with a documented complete response, partial response, and stable disease (CR + PR + SD) based on RECIST 1.1. This biomarker-positive sub-population is defined as those patients with phospho-STAT3 and/or nuclear β-catenin positivity on immunohistochemical (IHC) staining of Formalin Fixed Paraffin Embedded (FFPE) archival tissue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients with Adverse Events</measure>
    <time_frame>36 months</time_frame>
    <description>All patients who have received at least one dose of napabucasin will be included in the safety analysis according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) version 4.0. The incidence of adverse events will be summarized by type of adverse event and severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL)</measure>
    <time_frame>36 months</time_frame>
    <description>QoL will be measured using the European Organization for Research and Treatment of Cancer Quality of Life questionnaire (EORTC-QLQ-C30) in patients with pretreated metastatic CRC treated with napabucasin plus biweekly FOLFIRI versus biweekly FOLFIRI.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1250</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Napabucasin plus FOLFIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Addition of bevacizumab to the FOLFIRI regimen will be permissible. FOLFIRI chemotherapy infusion will start at least 2 hours following the first daily dose of napabucasin and will be administered every 2 weeks. Irinotecan/leucovorin infusion will follow bevacizumab infusion in selected patients to receive standard dose of bevacizumab (5 mg/kg). Irinotecan 180 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously, over approximately 90 minutes and 2 hours, respectively, starting on Day 1 of Cycle 1, following bevacizumab infusion or at least 2 hours following the first daily dose of napabucasin if bevacizumab is not administered. 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2) continuous infusion. This regimen will be repeated on Day 1 of every 14 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FOLFIRI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Addition of bevacizumab to the FOLFIRI regimen will be permissible. FOLFIRI chemotherapy infusion will be administered every 2 weeks. Irinotecan/leucovorin infusion will follow bevacizumab infusion in selected patients to receive standard dose of bevacizumab (5 mg/kg). Irinotecan 180 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously, over approximately 90 minutes and 2 hours, respectively, starting on Day 1 of Cycle 1, following bevacizumab infusion. 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2) continuous infusion. This regimen will be repeated on Day 1 of every 14 day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Napabucasin</intervention_name>
    <description>Napabucasin 240 mg will be administered orally, twice daily, with doses separated by approximately 12 hours (480 mg total daily dose).</description>
    <arm_group_label>Napabucasin plus FOLFIRI</arm_group_label>
    <other_name>BBI-608</other_name>
    <other_name>BBI608</other_name>
    <other_name>BB608</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <arm_group_label>Napabucasin plus FOLFIRI</arm_group_label>
    <arm_group_label>FOLFIRI</arm_group_label>
    <other_name>5-FU</other_name>
    <other_name>Carac</other_name>
    <other_name>Efudex</other_name>
    <other_name>Fluoroplex</other_name>
    <other_name>Adrucil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <arm_group_label>Napabucasin plus FOLFIRI</arm_group_label>
    <arm_group_label>FOLFIRI</arm_group_label>
    <other_name>Folinic Acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <arm_group_label>Napabucasin plus FOLFIRI</arm_group_label>
    <arm_group_label>FOLFIRI</arm_group_label>
    <other_name>Camptosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <arm_group_label>Napabucasin plus FOLFIRI</arm_group_label>
    <arm_group_label>FOLFIRI</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written, signed consent for trial participation must be obtained from the patient
             appropriately in accordance with applicable ICH guidelines and local and regulatory
             requirements prior to the performance of any study specific procedure.

          2. Must have histologically confirmed advanced CRC that is metastatic.

          3. Must have failed treatment with one regimen containing a fluoropyrimidine,
             oxaliplatin and bevacizumab for metastatic disease. All patients must have received a
             minimum of 6 weeks of the first-line regimen that included bevacizumab, oxaliplatin
             and a fluoropyrimidine in the same cycle. Treatment failure is defined as radiologic
             progression during or &lt; 6 months after the last dose of first-line therapy.

          4. FOLFIRI therapy is appropriate for the patient and is recommended by the
             Investigator.

          5. Imaging investigations including CT/MRI of chest/abdomen/pelvis or other scans as
             necessary to document all sites of disease performed within 21 days prior to
             randomization. Patients with either measurable disease or non-measurable evaluable
             disease are eligible.

          6. Must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.

          7. Must be ≥ 18 years of age.

          8. For male or female patient of child producing potential: Must agree to use
             contraception or take measures to avoid pregnancy during the study and for 180 days
             for female and male patients, of the final FOLFIRI dose. Patients who receive single
             agent napabucasin without FOLFIRI must agree to use contraception or take measures to
             avoid pregnancy during the study and for 30 days for female patients and 90 days for
             male patients, of the final napabucasin dose.

          9. Women of child bearing potential (WOCBP) must have a negative serum or urine
             pregnancy test within 5 days prior to randomization. The minimum sensitivity of the
             pregnancy test must be 25 IU/L or equivalent units of HCG.

         10. Must have alanine transaminase (ALT) ≤ 3 × institutional upper limit of normal (ULN)
             [≤ 5 × ULN in presence of liver metastases] within 14 days prior to randomization.

         11. Must have hemoglobin (Hgb) ≥ 9.0 g/dL within 14 days prior to randomization. Must not
             have required transfusion of red blood cells within 1 week of baseline Hgb
             assessment.

         12. Must have total bilirubin ≤ 1.5 × institutional ULN [≤ 2.0 x ULN in presence of liver
             metastases] within 14 days prior to randomization.

         13. Must have creatinine ≤ 1.5 × institutional ULN or Creatinine Clearance &gt; 50 ml/min
             (as calculated by the Cockcroft-Gault equation) within 14 days prior to
             randomization.

         14. Must have absolute neutrophil count ≥ 1.5 x 10^9/L within 14 days prior to
             randomization.

         15. Must have platelet count ≥ 100 x 10^9/L within 14 days prior to randomization. Must
             not have required transfusion of platelets within 1 week of baseline platelet
             assessment.

         16. Other baseline laboratory evaluations, listed in Section 6.0, must be done within 14
             days prior to randomization.

         17. Patient must consent to provision of, and Investigator(s) must confirm access to and
             agree to submit a representative formalin fixed paraffin block of tumor tissue in
             order that the specific correlative marker assays may be conducted. Submission of the
             tissue does not have to occur prior to randomization. Where local center regulations
             prohibit submission of blocks of tumor tissue, two 2 mm cores of tumor from the block
             and 10-30 unstained slides of whole sections of representative tumor tissue are
             preferred. Where two 2 mm cores of tumor from the block are unavailable, 10-30
             unstained slides of whole sections of representative tumor tissue alone are
             acceptable. Where no previously resected or biopsied tumor tissue exists or is
             available, on the approval of the Sponsor/designated CRO, the patient may still be
             considered eligible for the study.

         18. Patient must consent to provision of a sample of blood in order that the specific
             correlative marker assays may be conducted.

         19. Patients must be accessible for treatment and follow-up. Patients registered on this
             trial must receive protocol treatment and be followed at the participating center.
             This implies there must be reasonable geographical limits placed on patients being
             considered for this trial. Investigators must ensure that the patients randomized on
             this trial will be available for complete documentation of the treatment, response
             assessment, adverse events, and follow-up.

         20. Protocol treatment is to begin within 2 calendar days of patient randomization.

         21. The patient is not receiving therapy in a concurrent clinical study and the patient
             agrees not to participate in other interventional clinical studies during their
             participation in this trial while on study treatment. Patients participating in
             surveys or observational studies are eligible to participate in this study.

        Exclusion Criteria:

          1. Anti-cancer chemotherapy or biologic therapy if administered prior to the first
             planned dose of study medication (napabucasin or FOLFIRI) within period of time
             equivalent to the usual cycle length of the regimen. An exception is made for oral
             fluoropyrimidines (e.g. capecitabine, S-1), where a minimum of 10 days since last
             dose must be observed prior to the first planned dose of study medication. Standard
             dose of bevacizumab (5 mg/kg) may be administered prior to FOLFIRI infusion, per
             Investigator decision, for as long as permanent decision to include or exclude
             bevacizumab is made prior to patient randomization. Radiotherapy, immunotherapy
             (including immunotherapy administered for non-malignant disease neoplastic treatment
             purposes), or investigational agents within four weeks of first planned dose of
             napabucasin, with the exception of a single dose of radiation up to 8 Gy (equal to
             800 RAD) with palliative intent for pain control up to 14 days before randomization.

          2. More than one prior chemotherapy regimen administered in the metastatic setting.

          3. Major surgery within 4 weeks prior to randomization.

          4. Patients with any known brain or leptomeningeal metastases are excluded, even if
             treated.

          5. Women who are pregnant or breastfeeding. Women should not breastfeed while taking
             study treatment and for 4 weeks after the last dose of napabucasin or while
             undergoing treatment with FOLFIRI and for 180 days after the last dose of FOLFIRI.

          6. Gastrointestinal disorder(s) which, in the opinion of the Qualified/Principal
             Investigator, would significantly impede the absorption of an oral agent (e.g. active
             Crohn's disease, ulcerative colitis, extensive gastric and small intestine
             resection).

          7. Unable or unwilling to swallow napabucasin capsules daily.

          8. Prior treatment with napabucasin.

          9. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, clinically significant non-healing or healing wounds, symptomatic
             congestive heart failure, unstable angina pectoris, clinically significant cardiac
             arrhythmia, significant pulmonary disease (shortness of breath at rest or mild
             exertion), uncontrolled infection or psychiatric illness/social situations that would
             limit compliance with study requirements.

         10. Known hypersensitivity to 5-fluorouracil/leucovorin

         11. Known dihydropyrimidine dehydrogenase (DPD) deficiency

         12. Known hypersensitivity to irinotecan

         13. Abnormal glucuronidation of bilirubin, known Gilbert's syndrome

         14. Patients with QTc interval &gt; 470 milliseconds

         15. For patients to be treated with a regimen containing bevacizumab:

               -  History of cardiac disease: congestive heart failure (CHF) &gt; New York Heart
                  Association (NYHA) Class II; active coronary artery disease, myocardial
                  infarction within 6 months prior to study entry; unevaluated new onset angina
                  within 3 months or unstable angina (angina symptoms at rest) or cardiac
                  arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are
                  permitted).

               -  Current uncontrolled hypertension (systolic blood pressure [BP] &gt; 150 mmHg or
                  diastolic pressure &gt; 90 mmHg despite optimal medical management) as well as
                  prior history of hypertensive crisis or hypertensive encephalopathy.

               -  History of arterial thrombotic or embolic events (within 6 months prior to study
                  entry)

               -  Significant vascular disease (e.g., aortic aneurysm, aortic dissection,
                  symptomatic peripheral vascular disease)

               -  Evidence of bleeding diathesis or clinically significant coagulopathy

               -  Major surgical procedure (including open biopsy, significant traumatic injury,
                  etc.) within 28 days, or anticipation of the need for major surgical procedure
                  during the course of the study as well as minor surgical procedure (excluding
                  placement of a vascular access device or bone marrow biopsy) within 7 days prior
                  to study enrollment

               -  Proteinuria at screening as demonstrated by urinalysis with proteinuria ≥ 2+
                  (patients discovered to have ≥2+ proteinuria on dipstick urinalysis at baseline
                  should undergo a 24 hour urine collection and must demonstrate ≤ 1g of protein
                  in 24 hours to be eligible).

               -  History of abdominal fistula, gastrointestinal perforation, peptic ulcer, or
                  intra-abdominal abscess within 6 months

               -  Ongoing serious, non-healing wound, ulcer, or bone fracture

               -  Known hypersensitivity to any component of bevacizumab

               -  History of reversible posterior leukoencephalopathy syndrome (RPLS)

         16. Patients with a history of other malignancies except: adequately treated non-melanoma
             skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumors
             curatively treated with no evidence of disease for &gt; 3 years.

         17. Any active disease condition which would render the protocol treatment dangerous or
             impair the ability of the patient to receive protocol therapy.

         18. Any condition (e.g. psychological, geographical, etc.) that does not permit
             compliance with the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boston Biomedical</last_name>
    <phone>617-674-6800</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Alabama Oncology</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35223</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Hebert</last_name>
      <phone>205-263-9746</phone>
      <email>michelle.hebert@alabamaoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Associates, PC - HOPE</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85771</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Kirkwood</last_name>
      <phone>281-863-2587</phone>
      <email>Megan.Kirkwood@McKesson.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Comprehensive Blood and Cancer Center</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sudha Dara</last_name>
      <phone>661-616-1619</phone>
      <email>sdara@cbccusa.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>City of Hope- Comprehensive Care Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heera Pokhrel</last_name>
      <phone>626-218-0171</phone>
      <email>hpokhrel@coh.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Los Angeles Hematology Oncology Medical Group</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruma Barva</last_name>
      <phone>213-977-1214</phone>
      <email>rbarva@scoranet.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Joseph Heritage Healthcare</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Young</last_name>
      <phone>707-521-3814</phone>
      <email>kimberly.young@stjoe.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Kirkwood</last_name>
      <phone>281-863-2592</phone>
      <email>Megan.Kirkwood@McKesson.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Mary's Hospital &amp; Regional Med Center</name>
      <address>
        <city>Grand Junction</city>
        <state>Colorado</state>
        <zip>81501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Byerly</last_name>
      <phone>970-298-6575</phone>
      <email>amy.byerly@sclhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Hematology Consultants, PA</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Combs</last_name>
      <phone>302-623-4639</phone>
      <email>kcombs@christianacare.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Cancer Institute at Memorial Hospital</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mihaela Roldan</last_name>
      <phone>954-865-1864</phone>
      <email>MiRoldan@mhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baptist Health Medical Group Oncology, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolina Manchola-Orozco</last_name>
      <phone>305-595-2141</phone>
      <email>CarolinaMan@baptisthealth.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Piedmont Cancer Institute, PC</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Johnston</last_name>
      <phone>678-298-3241</phone>
      <email>ajohnston@piedmontcancerinstitute.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Specialists</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Kirkwood</last_name>
      <phone>281-863-2586</phone>
      <email>Megan.Kirkwood@McKesson.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Healthcare Research Network III, LLC</name>
      <address>
        <city>Tinley Park</city>
        <state>Illinois</state>
        <zip>60487</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mina Boyadzhieva</last_name>
      <phone>708-745-9971</phone>
      <email>mboyadzhieva@healthcareresearchnetwork.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern Medicine Cancer Center</name>
      <address>
        <city>Warrenville</city>
        <state>Illinois</state>
        <zip>60555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudine Gamster</last_name>
      <phone>630-315-1918</phone>
      <email>Claudine.Gamster@nm.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Parkview Research Center</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abby Reed</last_name>
      <phone>260-425-6811</phone>
      <email>Abby.reed@parkview.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indiana University Health Goshen Center for Cancer Care</name>
      <address>
        <city>Goshen</city>
        <state>Indiana</state>
        <zip>46526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa DePue</last_name>
      <phone>574-364-2649</phone>
      <email>vdepue@goshenhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Statesn Davis</last_name>
      <phone>316-613-4318</phone>
      <email>Statesn.davis@cancercenterofkansas.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Bebee</last_name>
      <phone>734-763-3803</phone>
      <email>pbe@med.umich.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology, P.A.</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Kirkwood</last_name>
      <phone>281-863-2588</phone>
      <email>Megan.Kirkwood@McKesson.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Francis Cancer Treatment Center</name>
      <address>
        <city>Grand Island</city>
        <state>Nebraska</state>
        <zip>68803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehmet Sitki Copur, MD</last_name>
      <phone>308-398-6518</phone>
      <email>clinicaltrials@sfmc-gi.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Missouri Valley Cancer Consortium</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Wilwerding</last_name>
      <phone>402-991-8070</phone>
      <phone_ext>202</phone_ext>
      <email>mwilwerding@mvcc.cc</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Research Network of Nebraska / Oncology Associates PC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tony Romero</last_name>
      <phone>402-991-8468</phone>
      <email>tromero@gucancer.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carol G. Simon Cancer Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Mackenzie</last_name>
      <phone>973-436-1755</phone>
      <email>mmackenzie@smgnj.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southeastern Medical Oncology Center</name>
      <address>
        <city>Goldsboro</city>
        <state>North Carolina</state>
        <zip>27534</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Grantham</last_name>
      <phone>919-580-0000</phone>
      <email>sgrantham@cancersmoc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toledo Clinic Cancer Centers</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pam Shoup</last_name>
      <phone>419-214-4236</phone>
      <email>pshoup@toledoclinic.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29412</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Drew Longshore</last_name>
      <phone>843-792-4271</phone>
      <email>longshor@musc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Cancer Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ghazala Mazhar, MD</last_name>
      <phone>901-683-0085</phone>
      <phone_ext>61227</phone_ext>
      <email>gmazhar@westclinic.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Austin Midtown</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>75705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Kirkwood</last_name>
      <phone>281-863-2586</phone>
      <email>Megan.Kirkwood@McKesson.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Dallas Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debora Jimerson</last_name>
      <phone>972-780-3406</phone>
      <email>debora.jimerson@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Denton South</name>
      <address>
        <city>Denton</city>
        <state>Texas</state>
        <zip>76210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Kirkwood</last_name>
      <phone>281-863-2589</phone>
      <email>Megan.Kirkwood@McKesson.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Fort Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Kirkwood</last_name>
      <phone>281-863-2586</phone>
      <email>Megan.Kirkwood@McKesson.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Millenium Oncology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Waldron</last_name>
      <phone>877-870-2640</phone>
      <email>JWaldron@wmrad.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Health Physicians Group</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzette Clark</last_name>
      <phone>972-428-4931</phone>
      <email>suzetteclark@texashealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Kirkwood</last_name>
      <phone>281-863-2586</phone>
      <email>Megan.Kirkwood@McKesson.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Kirkwood</last_name>
      <phone>281-863-2586</phone>
      <email>Megan.Kirkwood@McKesson.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Wichita Falls Texoma Cancer Center</name>
      <address>
        <city>Wichita Falls</city>
        <state>Texas</state>
        <zip>76310</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Kirkwood</last_name>
      <phone>281-863-2590</phone>
      <email>Megan.Kirkwood@McKesson.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northern Utah Associates</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shirley Waters</last_name>
      <phone>801-387-7166</phone>
      <email>nua.shirley@nmail.email</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>US Oncology - Virginia Cancer Specialists, PC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin Choquette</last_name>
      <phone>571-389-0873</phone>
      <email>karin.choquette@USOncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Hampton</city>
        <state>Virginia</state>
        <zip>23666</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Kirkwood</last_name>
      <phone>281-863-2591</phone>
      <email>Megan.Kirkwood@McKesson.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, P.C.</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98684</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Kirkwood</last_name>
      <phone>281-863-2586</phone>
      <email>Megan.Kirkwood@McKesson.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Imelda Ziekenhuis</name>
      <address>
        <city>Bonheiden</city>
        <state>Antwerpen</state>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doreen Iwens</last_name>
      <phone>+32 15 50 47 10</phone>
      <email>doreen.iwens@imelda.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Turnhout - Campus Sint-Elisabeth</name>
      <address>
        <city>Turnhout</city>
        <state>Antwerpen</state>
        <zip>2300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nel Bovin</last_name>
      <phone>+32 14 40 69 08</phone>
      <email>nel.bovin@azturnhout.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Erasme</name>
      <address>
        <city>Bruxelles</city>
        <state>Brussels Capital Region</state>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camilla Previtali</last_name>
      <phone>+32 25 55 44 55</phone>
      <email>camilla.previtali@erasme.ulb.ac.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Grand Hôpital de Charleroi - Site Notre-Dame</name>
      <address>
        <city>Charleroi</city>
        <state>Hainaut</state>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janique Dewelle</last_name>
      <phone>+32 71 10 47 09</phone>
      <email>janique.dewelle@ghdc.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Liège - Domaine Universitaire du Sart Tilman</name>
      <address>
        <city>Bruxelles</city>
        <state>Liège</state>
        <zip>1050</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Evrard</last_name>
      <phone>+32 42 84 38 11</phone>
      <email>linda.evrard@chu.ulg.ac.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven - Campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hilde Marsé</last_name>
      <phone>+32 16 34 75 83</phone>
      <email>hilde.marse@uzleuven.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan Brugge - Oostende - Campus Sint-Jan</name>
      <address>
        <city>Brugge</city>
        <state>West-Vlaanderen</state>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Van Massenhove</last_name>
      <phone>+32 50 45 25 54</phone>
      <email>deborah.vanmassenhove@azsintjan.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Lucas - Campus Sint-Lucas</name>
      <address>
        <city>Brugge</city>
        <state>West-Vlaanderen</state>
        <zip>8310</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tania Maerten</last_name>
      <phone>+32 50 36 90 57</phone>
      <email>tania.maerten@stlucas.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Henderson</last_name>
      <phone>613-737-7700</phone>
      <phone_ext>70550</phone_ext>
      <email>ahenderson@toh.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Michael's Hospital Li Ka Shing Knowledge Institute</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Skitch</last_name>
      <phone>416-864-6060</phone>
      <phone_ext>2084</phone_ext>
      <email>skitcha@smh.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Masarykuv onkologicky ustav</name>
      <address>
        <city>Brno</city>
        <zip>656 53</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petra Sevelova</last_name>
      <phone>+420-543-136-220</phone>
      <email>petra.sevelova@mou.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leopoldina Krankenhaus Med. Klinik 2</name>
      <address>
        <city>Schweinfurt</city>
        <state>Bayern</state>
        <zip>97422</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katja Richter</last_name>
      <phone>+49-97-217-2024-11</phone>
      <email>krichter@leopoldina.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Schwerpunkpraxis für Hämatologie und Onkologie</name>
      <address>
        <city>Magdeburg</city>
        <state>Sachsen-Anhalt</state>
        <zip>39104</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Statesnne Kroening</last_name>
      <phone>+49-3915616568</phone>
      <email>Statesnne.kroening@onkologie-magdeburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Am Urban</name>
      <address>
        <city>Berlin</city>
        <zip>10967</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anja Müller</last_name>
      <phone>+49-30-130-2221-60</phone>
      <email>anja.mueller5@vivantes.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MVZ Onkologischer Schwerpunkt am Oskar-Helene-Heim</name>
      <address>
        <city>Berlin</city>
        <zip>14195</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Swetlana Wahnke</last_name>
      <phone>+49-30-644-9952-27</phone>
      <email>akirsch99@t-online.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Facharztzentrum Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20249</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Detlef-Andreas Fabian</last_name>
      <phone>+49-40-41467893</phone>
      <email>studienzentrale@onkologie-eppendorf.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aichi Cancer Center Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Shikoku Cancer Center</name>
      <address>
        <city>Matsunami</city>
        <state>Ehime</state>
        <zip>791-0280</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kobe City Medical Center General Hospital</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>650-0047</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ST. Marianna University School of Medicine</name>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa</state>
        <zip>216-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka Medical College Hospital</name>
      <address>
        <city>Takatsuki</city>
        <state>Osaka</state>
        <zip>569-8686</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saitama Cancer Center</name>
      <address>
        <city>Kita-Adachi</city>
        <state>Saitama</state>
        <zip>362-0806</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shizuoka Cancer Center</name>
      <address>
        <city>Sunto</city>
        <state>Shizuoka</state>
        <zip>411-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Hospital, Tokyo Medical and Dental University</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The cancer insitute hospital of JFCR (Japanese Foundation For Cancer Research)</name>
      <address>
        <city>Koto-ku</city>
        <state>Tokyo</state>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Kyushu Cancer Center</name>
      <address>
        <city>Fukuoka</city>
        <zip>811-1395</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka Medical Center for Cancer and Cardiovascular Diseases</name>
      <address>
        <city>Osaka</city>
        <zip>537-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <state>Friesland</state>
        <zip>8934 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tineke Rienks</last_name>
      <phone>+31-58-286-6666</phone>
      <email>tineke.rienks@znb.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Elizabeth Tweesteden Ziekenhuis locatie Tilburg</name>
      <address>
        <city>Tilburg</city>
        <zip>5042 SB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emile Maassen</last_name>
      <phone>+31-13-465-5234</phone>
      <email>onco-research@tsz.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 25, 2017</lastchanged_date>
  <firstreceived_date>April 25, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal Neoplasms</keyword>
  <keyword>Colonic Diseases</keyword>
  <keyword>Digestive System Diseases</keyword>
  <keyword>Digestive System Neoplasms</keyword>
  <keyword>Gastrointestinal Diseases</keyword>
  <keyword>Gastrointestinal Neoplasms</keyword>
  <keyword>Intestinal Diseases</keyword>
  <keyword>Intestinal Neoplasms</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Neoplasms by Histologic Type</keyword>
  <keyword>Neoplasms by Site</keyword>
  <keyword>Neoplasms, Glandular and Epithelial</keyword>
  <keyword>Rectal Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
